A flurry of good news
The combined trading and strategic update from Northbridge reports progress across several areas....
Read moreUPGS on track to scale new revenue heights
UPGS’s achievement of 13.7% revenue growth in the first half of FY2022 and anticipation of full...
Read moreVery welcome regulatory clarity
Destiny Pharma has announced details of positive feedback from the European Medicines Agency (EMA)...
Read more'Transformational’ FY21 results
It is worth reiterating the huge scale of the market opportunity Arqit Quantum addresses....
Read more
Consensus met, record revenue and profits
The trading update for FY21 was encouraging, with results in-line with consensus expectations and...
Read moreM3’s profile rising further
In a spree of positive updates to start 2022, Destiny Pharma begins the year with the profile of...
Read moreTime to buy the dip
Eleco is an IRP-rich firm that is trading at an unjustified discount to peers (2.4x fwd EV/sales vs...
Read moreReasons for optimism
Despite the delay, the results for the year to September were in-line with expectations at the adj....
Read moreWell positioned for strong sales growth in FY2022
ASC announced around 20% sales growth in a FY2021 trading update released today. Sales growth was...
Read moreEarly strategic progress not reflected in valuation
H1 ‘22 results (to 30 Nov ‘21) show steady progress on key metrics, with signs that Time’s refined...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
